[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355665-105":59,"doc-detail-355665-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","single-cell-transcriptomics-identifies-bst2-as-an-oncogenic-driver-and-immunotherapy-biomarker-in-lung-adenocarcinoma","Single-Cell Transcriptomics Identifies BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma","","Single-cell transcriptomics clarifies how Bone marrow stromal cell antigen 2 (BST2) contributes to lung adenocarcinoma (LUAD) malignancy and immune evasion. The study integrates scRNA-seq from primary LUAD and normal tissues with TCGA-LUAD and GEO bulk RNA-seq cohorts, using inferCNV, trajectory, cell–cell communication, and hdWGCNA to map malignant transformation and TME interactions. Differential expression, survival, GSEA, and in vitro assays validate BST2’s oncogenic function, while TIDE and drug screening link high BST2 to impaired immune checkpoint blockade efficacy.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/single-cell-transcriptomics-identifies-bst2-as-an-oncogenic-driver-and-immunotherapy-biomarker-in-lung-adenocarcinoma/355665/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/single-cell-transcriptomics-identifies-bst2-as-an-oncogenic-driver-and-immunotherapy-biomarker-in-lung-adenocarcinoma/355665.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main biological question of the study?","Question",{"text":112,"@type":113},"The study investigates how BST2 drives LUAD malignancy and how it relates to immune evasion within the tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were single-cell and bulk transcriptomic datasets used?",{"text":117,"@type":113},"Single-cell RNA sequencing was analyzed to identify malignant epithelial populations and their trajectories, while bulk RNA-seq from TCGA-LUAD and GEO cohorts was integrated to support validation and broader pattern assessment.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports BST2 as an oncogenic driver in LUAD?",{"text":121,"@type":113},"BST2 upregulation in malignant cells and TAMs is linked to poor prognosis, GSEA shows enrichment in oncogenic pathways, and in vitro experiments demonstrate that BST2 knockdown suppresses LUAD cell proliferation, migration, and invasion.",{"name":123,"@type":110,"acceptedAnswer":124},"How does BST2 relate to immunotherapy response?",{"text":125,"@type":113},"Higher BST2 expression is associated with reduced efficacy of immune checkpoint blockade, and TIDE-based evaluation is used to assess its relationship with immunotherapy response.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},355665,1790410456,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Mediators of Inflammation  \n SPECIAL ISSUE  Inflammation and Immune Signal Transduction at Single-Cell Resolution  \nRESEARCH ARTICLE OPEN ACCESS   \nSingle-Cell Transcriptomics Identiﬁes BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma  \nKeyun Zhu  | Mingrong Lin  | Chengbin Lin | Tao Hu  | Zhikai Cao  | Shuo Huang  | Yan Shen  | Jing Zeng  | Jinxian He  | Weiyu Shen  | Jianjian Ying   \nDepartment of Thoracic Surgery, The Afﬁliated LiHuiLi Hospital of Ningbo University, Ningbo 315040, Zhejiang, China  \nCorrespondence: Jinxian He ([lhlhejinxian@nbu.edu.cn](lhlhejinxian@nbu.edu.cn)) | Weiyu Shen ([shenweiyu@nbu.edu.cn](shenweiyu@nbu.edu.cn)) | Jianjian Ying ([lhlyingjianjian@nbu.edu.cn](lhlyingjianjian@nbu.edu.cn))  \nReceived: 29 December 2025 | Revised: 11 March 2026 | Accepted: 6 April 2026  \nGuest Editor: Liu Jinhui  \nKeywords: immune cells | LUAD | TME  \nABSTRACT  \nBackground: Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality worldwide. The tumor microenvironment (TME) plays a pivotal role in LUAD progression, but the speciﬁc molecular mechanisms driving malignancy and immune evasion remain incompletely understood. Bone marrow stromal cell antigen 2 (BST2) has been implicated in other cancers, yet its functional role and therapeutic potential in LUAD require further elucidation.  \nMethods: We integrated single-cell RNA sequencing (scRNA-seq) data from primary LUAD tissues and normal lung tissues with bulk RNA-seq data from The Cancer Genome Atlas (TCGA)–LUAD and GEO cohorts. Malignant epithelial cells were identiﬁed using inferCNV analysis. Cellular trajectory and cell–cell communication analyses were systematically performed to delineate the malignant transformation process and its interactions with the TME. High-dimensional weighted gene coexpression network analysis further identiﬁed key functional modules within malignant subpopulations. The oncogenic role of BST2 was comprehensively validated through differential expression analysis, survival analysis, gene set enrichment analysis (GSEA), and in vitro cellular assays, including RT‑qPCR, MTT, colony formation, Transwell invasion, and wound healing experiments. In addition, we employed the tumor immune dysfunction and exclusion (TIDE) algorithm to evaluate its association with immunotherapy response and performed drug screening via the Clue.io platform to explore its therapeutic potential.  \nResults: scRNA-seq analysis revealed signiﬁcant heterogeneity in the TME and identiﬁed two distinct subpopulations of malignant epithelial cells. Trajectory analysis uncovered a speciﬁc lineage (Lineage 4) driving the normal-to-malignant transition, while cell communication analysis highlighted interactions between malignant cells and tumor-associated macrophages (TAMs) mediated by MIF and APP signaling pathways. High-dimensional weighted gene coexpression network analysis (hdWGCNA) identiﬁed a coexpression gene module (Module 1) speciﬁcally enriched in malignant subpopulations. By intersecting with a set of immunoregulatory genes, BST2 was ultimately determined as a key candidate oncogene. BST2 was signiﬁcantly upregulated in malignant epithelial cells and TAMs, and its high expression was closely associated with poor patient prognosis. GSEA demonstrated that high BST2 expression was linked to the activation of crucial oncogenic pathways, including oxidative phosphorylation, Kras signaling, and epithelial–mesenchymal transition (EMT) . In vitro validation further conﬁrmed that BST2 knockdown  \nKeyun Zhu, Mingrong Lin, and Chengbin Lin contributed equally to this work.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nCopyright © 2026 Keyun Zhu et al. Mediators of Inﬂammation published by John Wiley & Sons Ltd.  \nsuppressed LUAD cell proliferation, migration, and invasion. Furthe","cbCaisNYTs4YGiob","https://ap.wps.com/l/cbCaisNYTs4YGiob","pdf",13459635,17,"English","# Abstract\n# Introduction\n## Background and clinical context\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main biological question of the study?\",\"answer\":\"The study investigates how BST2 drives LUAD malignancy and how it relates to immune evasion within the tumor microenvironment.\"},{\"question\":\"How were single-cell and bulk transcriptomic datasets used?\",\"answer\":\"Single-cell RNA sequencing was analyzed to identify malignant epithelial populations and their trajectories, while bulk RNA-seq from TCGA-LUAD and GEO cohorts was integrated to support validation and broader pattern assessment.\"},{\"question\":\"What evidence supports BST2 as an oncogenic driver in LUAD?\",\"answer\":\"BST2 upregulation in malignant cells and TAMs is linked to poor prognosis, GSEA shows enrichment in oncogenic pathways, and in vitro experiments demonstrate that BST2 knockdown suppresses LUAD cell proliferation, migration, and invasion.\"},{\"question\":\"How does BST2 relate to immunotherapy response?\",\"answer\":\"Higher BST2 expression is associated with reduced efficacy of immune checkpoint blockade, and TIDE-based evaluation is used to assess its relationship with immunotherapy response.\"}]","Single-Cell Transcriptomics Identifies BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma | PDF",1790120416,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39c9b19f42f277d34f9a69e9e9f8ef94.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a3a59837de399a0268569f81e7aa826.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e10ccc9e000e97aa0fbf9d752f940f32.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6179132eccb45585862d6c6211fdeb2.webp",980,1287]